Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Chimeric Therapeutics Ltd. (AU:CHM)
ASX:CHM
Holding AU:CHM?
Track your performance easily
CHM Stock Chart & Stats
Day’s RangeAU$0 - AU$0
52-Week RangeAU$0.02 - AU$0.05
Previous CloseAU$0.02
Volume2.32M
Average Volume (3M)1.15M
Market Cap
AU$13.40M
Enterprise Value-AU$4.98M
Total Cash (Recent Filing)AU$18.38M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.60
Next Earnings
Sep 27, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares OutstandingN/A
10 Day Avg. Volume908,864
30 Day Avg. Volume1,154,202
Standard Deviation0.19
R-Squared0.21
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)21654.24
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Chimeric Therapeutics Ltd. News
PremiumCompany Announcements
Chimeric Advances Cancer Cell Therapy Trials
PremiumCompany Announcements
Chimeric Therapeutics Issues New Employee Incentive Options
PremiumCompany Announcements
Chimeric Therapeutics Seeks New ASX Quotation
PremiumCompany Announcements
Chimeric Therapeutics Cuts Annual Losses
PremiumCompany Announcements
Chimeric Begins Landmark Cancer Therapy Trial
PremiumCompany Announcements
Chimeric Therapeutics Gains $1.5M R&D Advance
PremiumCompany Announcements
Chimeric Therapeutics Expands CAR T Trials in Australia
PremiumCompany Announcements
Chimeric Therapeutics Seeks New Share QuotationOptions Prices
Currently, No data available
---
Ownership Overview
14.27% Insiders
0.00% Mutual Funds
0.00% Other Institutional Investors
85.73% Public Companies and
Individual Investors
CHM FAQ
What was Chimeric Therapeutics Ltd.’s price range in the past 12 months?
Chimeric Therapeutics Ltd. lowest share price was AU$0.01 and its highest was AU$0.05 in the past 12 months.
What is Chimeric Therapeutics Ltd.’s market cap?
Currently, no data Available
When is Chimeric Therapeutics Ltd.’s upcoming earnings report date?
Chimeric Therapeutics Ltd.’s upcoming earnings report date is Sep 27, 2024 which is in 7 days.
How were Chimeric Therapeutics Ltd.’s earnings last quarter?
Chimeric Therapeutics Ltd. released its earnings results on Feb 28, 2024. The company reported AU$0.004 earnings per share for the quarter, beating the consensus estimate of -AU$0.02 by AU$0.024.
Is Chimeric Therapeutics Ltd. overvalued?
According to Wall Street analysts Chimeric Therapeutics Ltd.’s price is currently Overvalued.
Does Chimeric Therapeutics Ltd. pay dividends?
Chimeric Therapeutics Ltd. does not currently pay dividends.
What is Chimeric Therapeutics Ltd.’s EPS estimate?
Chimeric Therapeutics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Chimeric Therapeutics Ltd. have?
Chimeric Therapeutics Ltd. has 893,611,400 shares outstanding.
What happened to Chimeric Therapeutics Ltd.’s price movement after its last earnings report?
Chimeric Therapeutics Ltd. reported an EPS of AU$0.004 in its last earnings report, beating expectations of -AU$0.02. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Chimeric Therapeutics Ltd.?
Currently, no hedge funds are holding shares in AU:CHM
---
Chimeric Therapeutics Ltd. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.00%
12-Months-Change
Fundamentals
Return on Equity
-308.21%
Trailing 12-Months
Asset Growth
-31.74%
Trailing 12-Months
Company Description
Chimeric Therapeutics Ltd.
Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells.
---
Technical Analysis
Australian Clinical Labs Ltd
―
Race Oncology Ltd.
―
Radiopharm Theranostics Limited
―
---